- Report
- March 2024
- 188 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- March 2024
- 195 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Drug Pipelines
- April 2024
- 230 Pages
Global
From €2900EUR$3,000USD£2,491GBP
- Clinical Trials
- April 2024
- 115 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1208EUR$1,250USD£1,038GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1208EUR$1,250USD£1,038GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1208EUR$1,250USD£1,038GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- November 2023
- 30 Pages
Global
From €3142EUR$3,250USD£2,699GBP
Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more